Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Juan P. Frías, Stanley H. Hsia, Sarah Eyde, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 472-483
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Haiqiang Yao, Anqi Zhang, Delong Li, et al.
BMJ (2024), pp. e076410-e076410
Open Access | Times Cited: 139
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Obesity in adults
Ildiko Lingvay, Ricardo V. Cohen, Carel W. le Roux, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 972-987
Closed Access | Times Cited: 52
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Ryan J. Jalleh, Christopher K. Rayner, Trygve Hausken, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 957-964
Closed Access | Times Cited: 18
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Nasreen Alfaris, Stephanie W. Waldrop, Veronica Johnson, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102782-102782
Open Access | Times Cited: 16
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, et al.
Metabolism (2023) Vol. 149, pp. 155710-155710
Closed Access | Times Cited: 27
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Richard Le, Mau T. Nguyen, Momina A. Allahwala, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4674-4674
Open Access | Times Cited: 10
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta, Lakshmi Nagendra, Beatrice Anne, et al.
Obesity Science & Practice (2024) Vol. 10, Iss. 2
Open Access | Times Cited: 9
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential
Y. Cho, Soyeon Kim, Pan-Kyung Kim, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 291-291
Open Access | Times Cited: 1
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Prathima Gogineni, Eka Melson, Dimitris Papamargaritis, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 7, pp. 801-818
Open Access | Times Cited: 7
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 7
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Janet B. McGill, Irl B. Hirsch, Christopher G. Parkin, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1085-1098
Open Access | Times Cited: 5
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Juan José Gorgojo Martínez
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 678-678
Open Access
Efficacy of GLP-1 receptor agonists on weight loss, body mass index and waist circumference for obese or overweight patients: A systematic review, meta-analysis and meta-regression of 47 randomized-controlled trials
Hon Jen Wong, Bryan Sim, Yao Hao Teo, et al.
(2025)
Closed Access
Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)
Yuxiang Tu, Haoyong Yu
Metabolism and Target Organ Damage (2025)
Open Access
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis
Shaolong Zhang, Boran Yu, Jiamin Xu, et al.
Diabetes Technology & Therapeutics (2025)
Closed Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Page 1 - Next Page

Scroll to top